GeneFerm Biotechnology Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	677.1	521.16	793.77	633.96	522.33
Revenue Growth (YoY)	29.92%	-34.34%	25.21%	21.37%	41.82%
Cost of Revenue	486.3	424.42	507.42	411.8	329.68
Gross Profit	190.8	96.75	286.35	222.16	192.65
Selling, General & Admin	111.22	102.93	104.88	96.71	88.82
Research & Development	33.54	29.31	28.33	24.18	23.56
Operating Expenses	144.72	131.15	132.79	120.17	113.82
Operating Income	46.08	-34.41	153.57	101.99	78.84
Interest Expense	-6.22	-4.44	-4.17	-3.82	-7.32
Interest & Investment Income	1.82	1.54	0.92	0.33	0.21
Currency Exchange Gain (Loss)	-9.11	4.8	0.84	9.66	-2.67
Other Non Operating Income (Expenses)	2.42	5.03	2.27	2.6	1.51
EBT Excluding Unusual Items	34.98	-27.49	153.42	110.76	70.57
Gain (Loss) on Sale of Investments	-	-	-	-0.43	-
Gain (Loss) on Sale of Assets	-0.28	0.02	0.01	-0.11	0.04
Other Unusual Items	-	-	-	-	-0.21
Pretax Income	34.7	-27.47	153.43	110.21	70.4
Income Tax Expense	5.83	-4.94	28.81	16.76	12.98
Net Income	28.86	-22.53	124.62	93.45	57.41
Net Income to Common	28.86	-22.53	124.62	93.45	57.41
Net Income Growth	-	-	33.35%	62.78%	1167.67%
Shares Outstanding (Basic)	41	41	41	41	40
Shares Outstanding (Diluted)	42	41	42	43	46
Shares Change (YoY)	0.11%	-0.36%	-2.26%	-8.00%	65.83%
EPS (Basic)	0.70	-0.54	3.01	2.26	1.45
EPS (Diluted)	0.70	-0.54	2.99	2.20	1.32
EPS Growth	-	-	35.63%	66.87%	725.71%
Free Cash Flow	75.89	-14.31	120.37	-155.74	-32.65
Free Cash Flow Per Share	1.83	-0.34	2.89	-3.66	-0.70
Dividend Per Share	0.700	-	2.000	1.500	1.000
Dividend Growth	-	-	33.33%	50.00%	1103.93%
Gross Margin	28.18%	18.56%	36.08%	35.04%	36.88%
Operating Margin	6.80%	-6.60%	19.35%	16.09%	15.09%
Profit Margin	4.26%	-4.32%	15.70%	14.74%	10.99%
Free Cash Flow Margin	11.21%	-2.74%	15.17%	-24.57%	-6.25%
EBITDA	113.48	37.89	219.41	145.16	117.76
EBITDA Margin	16.76%	7.27%	27.64%	22.90%	22.55%
D&A For EBITDA	67.41	72.3	65.84	43.16	38.92
EBIT	46.08	-34.41	153.57	101.99	78.84
EBIT Margin	6.80%	-6.60%	19.35%	16.09%	15.09%
Effective Tax Rate	16.81%	-	18.78%	15.21%	18.44%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.